Tandem Diabetes Care, Inc. reported its financial results for the second quarter ended June 30, 2025. The company announced sales of $240.678 million, an 8% increase compared to $221.910 million in the second quarter of 2024. U.S. pump shipments increased during the quarter, contributing to the overall sales growth.
Gross profit for the second quarter was $125.855 million, resulting in a gross margin of 52%, an improvement from 51% in Q2 2024. However, Tandem reported an operating loss of $(51.810) million, compared to an operating loss of $(30.774) million in the prior year period. This operating loss included $19.951 million in litigation and settlement expense.
The net loss for Q2 2025 was $(52.400) million, or $(0.78) per share, compared to a net loss of $(30.814) million, or $(0.47) per share, in Q2 2024. For the full year 2025, the company narrowed its worldwide sales guidance to $1 billion, which was the high end of its previous range of $997 million to $1 billion. Tandem reiterated its gross margin expectation of approximately 54% and adjusted EBITDA of approximately 3% of sales for the full year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.